TL;DR: GEn1E Lifesciences is a Y Combinator Summer 2019 startup AI platform accelerating therapies for rare & inflammatory diseases., currently active with an early-stage team.
AI platform accelerating therapies for rare & inflammatory diseases.
Last verified:
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace a…
Built by LemStudio
Yes. GEn1E Lifesciences was funded by Y Combinator in the Summer 2019 batch. AI platform accelerating therapies for rare & inflammatory diseases.
GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protei…
GEn1E Lifesciences was part of Y Combinator's Summer 2019 batch.
GEn1E Lifesciences is currently listed as Active in Y Combinator's directory.
Loading interactive view…